RP-1776, a novel cyclic peptide produced by Streptomyces sp., inhibits the binding of PDGF to the extracellular domain of its receptor

J Antibiot (Tokyo). 2001 May;54(5):405-14. doi: 10.7164/antibiotics.54.405.

Abstract

RP-1776, a novel cyclic peptide, was isolated from the culture broth of Streptomyces sp. KY11784. RP-1776 selectively inhibited the binding of PDGF BB to the extracellular domain of the PDGF beta-receptor with an IC50 value of 11 +/- 6 microM. Detailed binding experiments suggested that RP-1776 directly interacts with PDGF BB. RP-1776 inhibited the phosphorylation of the PDGF beta-receptor induced by PDGF BB. These results suggested that RP-1776 antagonizes the signaling of PDGF BB probably through the inhibition of PDGF BB binding to the PDGF beta-receptor.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / isolation & purification*
  • Anti-Bacterial Agents / pharmacology*
  • Becaplermin
  • CHO Cells
  • Cricetinae
  • Depsipeptides
  • Fermentation
  • Inhibitory Concentration 50
  • Magnetic Resonance Spectroscopy
  • Microbial Sensitivity Tests
  • Peptides, Cyclic / chemistry
  • Peptides, Cyclic / isolation & purification*
  • Peptides, Cyclic / pharmacology*
  • Phosphorylation / drug effects
  • Platelet-Derived Growth Factor / antagonists & inhibitors*
  • Platelet-Derived Growth Factor / metabolism
  • Protein Structure, Tertiary
  • Proto-Oncogene Proteins c-sis
  • Receptors, Platelet-Derived Growth Factor / metabolism*
  • Soil Microbiology
  • Streptomyces / chemistry*
  • Streptomyces / metabolism

Substances

  • Anti-Bacterial Agents
  • Depsipeptides
  • Peptides, Cyclic
  • Platelet-Derived Growth Factor
  • Proto-Oncogene Proteins c-sis
  • platelet-derived growth factor A
  • skyllamycins
  • Becaplermin
  • Receptors, Platelet-Derived Growth Factor